Articles related to PROSTATE CANCER

New research reveals significant differences in overall survival rates based on the site of visceral metastases in metastatic prostate cancer. Discover how these insights could shape your approach to patient care.

Discover how real-world data on 177Lu PSMA validates its efficacy in mCRPC treatment, providing actionable early markers for therapeutic response. Learn how these findings can enhance your clinical decision-making.

New research questions the life-extending efficacy of most common cancer screenings, emphasizing the need for transparent physician-patient discussions to weigh the risks and benefits. Learn more about this crucial topic that might change your approach to recommending screenings.

The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.

The ASCO 2023 meeting has unveiled key studies in prostate cancer, including insights into PSA levels post-radiation therapy, the role of BRCA mutations, and promising combination therapies.

The FDA’s approval of the olaparib, abiraterone, and prednisone regimen for BRCA-mutated mCRPC, based on the PROpel trial, could significantly alter the treatment landscape. Learn more about this promising development in prostate cancer therapy.